Annexon, Inc.

ANNX · Nasdaq · United States

Share price · ANNX

$3.52-1.76 (-33.33%) 3M

close as of 2026-11-18 · 24h delayed · vol 3.0M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ANNX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 19 Oct 2026+17.6%
  2. 28 Sep 2026+10.2%
  3. 15 Jul 2026+17.1%

    Nothing announced by ANNX that day or the session before.

  4. 8 Jul 2026-7.3%
  5. 6 Jul 2026+9.2%
  6. 17 Jun 2026+9.3%
  7. 10 Jun 2026-9.2%

    Nothing announced by ANNX that day or the session before.

  8. 21 May 2026+7.9%

    Nothing announced by ANNX that day or the session before.

  9. 15 Apr 2026+9.5%

    Nothing announced by ANNX that day or the session before.

  10. 10 Mar 2026+8.8%

    Nothing announced by ANNX that day or the session before.

Share of unusual movement by asset

For each asset, the share of ANNX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
Complement C1qMonoclonal antibody
Huntington's DiseaseGuillain-Barré Syndrome
Phase 3
Complement C1qAntibody fragment
Age-Related Macular DegenerationGeographic Atrophy
ANX009No recent activity
Phase 1
C1qAntibody fragment
Systemic Lupus Erythematosus

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
May 2027 (1)
tanruprubartPhase 3Guillain-Barre Syndrome
Est. primary completion 2027-05-31 · NCT07020819 · CT.gov ↗
What to watch
July 2027 (1)
VonaprumentPhase 3Geographic Atrophy
Est. primary completion 2027-07-31 · NCT06510816 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
VonaprumentPhase 3Geographic Atrophy
Est. primary completion 2029-07-31 · NCT07807969 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 January 2026Filing submittedtanruprubartMarketing authorisation application submitted to the EMA for tanruprubart in Guillain-Barré syndrome
EU, EMA · Annexon, Inc. · Source ↗
4 June 2024Topline resulttanruprubartPivotal Phase 3 (NCT04701164) topline: ANX005 30 mg/kg met the primary endpoint (GBS-DS at week 8)
Global · Annexon, Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$41M$103M+ $111M short-term inv.$51M-$49M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$47M$200M+ $10.0M short-term inv.$55M-$48M operating cash flowreport ↗
2026-Q1—$36M$176M+ $50M short-term inv.$44M-$47M operating cash flowreport ↗
2025-Q3—$50M$140M+ $49M short-term inv.$55M-$52M operating cash flowreport ↗
2025-Q2—$44M$133M+ $95M short-term inv.$49M-$38M operating cash flowreport ↗
2025-Q1—$48M$98M+ $167M short-term inv.$54M-$50M operating cash flowreport ↗
2024-Q3—$30M$81M+ $261M short-term inv.$35M-$32M operating cash flowreport ↗
2024-Q2—$25M$158M+ $211M short-term inv.$30M-$22M operating cash flowreport ↗
2024-Q1—$21M$153M+ $113M short-term inv.$25M-$28M operating cash flowreport ↗
2023-Q3—$28M$134M+ $32M short-term inv.$32M-$28M operating cash flowreport ↗
2023-Q2—$30M$115M+ $79M short-term inv.$35M-$36M operating cash flowreport ↗
2023-Q1—$32M$145M+ $84M short-term inv.$39M-$33M operating cash flowreport ↗
2022-Q3—$28M$212M+ $59M short-term inv.$35M-$31M operating cash flowreport ↗
2022-Q2—$29M$106M+ $73M short-term inv.$37M-$28M operating cash flowreport ↗
2022-Q1—$27M$114M+ $94M short-term inv.$35M-$30M operating cash flowreport ↗
2021-Q3—$28M$70M+ $203M short-term inv.$36M-$30M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$185M$163M+ $76M short-term inv.$52M-$186M operating cash flowreport ↗

Annexon did not report revenue for fiscal 2025. R&D expense totaled $184.7M, up 54.6% YoY, while cash, cash equivalents and short-term investments were approximately $238.3M as of December 31, 2025. The company reported a net loss of $206.69M.

The company guided to an anticipated cash runway into the second half of 2027. Clinical milestones include topline Phase 3 ARCHER II data for vonaprument in geographic atrophy expected in Q4 2026, a Marketing Authorization Application filed in Europe for tanruprubart with FORWARD study data expected to support a planned BLA submission in 2026, and proof-of-concept data for ANX1502 anticipated in 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$119M$51M+ $263M short-term inv.$35M-$118M operating cash flowreport ↗
2023-FY—$114M$226M+ $35M short-term inv.$34M-$121M operating cash flowreport ↗
2022-FY—$113M$141M+ $103M short-term inv.$35M-$116M operating cash flowreport ↗
2021-FY—$100M$76M+ $168M short-term inv.$33M-$106M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 9 purchases ($5.5M), 10 sales ($313K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-24Love Douglas · director, PRESIDENT AND CEOOpen-market purchase26,065$3.83$100KForm 4
2026-08-10Blumenkranz Mark S. · directorAward / grant (derivative)175,000——Form 4
2026-06-11Yednock Ted · EVP & CHIEF INNOVATION OFFICEROption exercise30,646$1.85$57KForm 4
2026-06-11Carson William H. · directorAward / grant (derivative)65,000——Form 4
2026-06-11Choi Jung · directorAward / grant (derivative)65,000——Form 4
2026-06-11Cockroft Bettina M. · directorAward / grant (derivative)65,000——Form 4
2026-06-11JONES WILLIAM A JR · directorAward / grant (derivative)65,000——Form 4
2026-06-11Satter Muneer A · directorAward / grant (derivative)65,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 217 reporting institutions held 155.9M shares ($855.6M, 82.3% of shares outstanding).

#InstitutionSharesValue
1Redmile Group, LLC14,549,768$80.6M
2BlackRock, Inc.10,938,509$60.6M
3FMR LLC10,635,648$58.9M
4BVF INC/IL8,698,173$48.2M
5STATE STREET CORP6,919,255$38.3M
6VANGUARD CAPITAL MANAGEMENT LLC5,956,589$33.0M
7Bain Capital Life Sciences Investors, LLC5,212,674$28.9M
8Bellevue Group AG5,157,290$28.6M
9MAK CAPITAL ONE LLC4,724,043$26.2M
10ADAGE CAPITAL PARTNERS GP, L.L.C.4,300,000$23.8M
11BANK OF AMERICA CORP /DE/4,259,995$23.6M
12Nuveen, LLC4,246,330$23.5M
13Siren, L.L.C.3,958,646$21.9M
14Balyasny Asset Management L.P.3,886,909$21.5M
15AMERIPRISE FINANCIAL INC3,449,121$19.1M